Pulmonx Corporation (NasdaqGS: LUNG)
Health Care · Health Care Equipment & Supplies · US
$2.50
+9.65% today · +49.7% 1Y
Pulmonx Corporation (NasdaqGS: LUNG) operates in the Health Care Equipment & Supplies industry within the Health Care sector. The company is valued at $107.37M and employs 296 people.
Over the last twelve months the share price has gained 49.7%, trading between 1.13 and 2.89.
Tweenvest scores Pulmonx Corporation across four factors: quality 28/100, value 55/100, growth 92/100. Its strongest factor is growth.
LUNG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $107.37M
- Revenue (TTM)
- $87.44M
- P/E
- —
- EPS
- -1.15
- Dividend yield
- —
- Beta (5Y)
- 0.28
- 52-week high
- $2.89
- 52-week low
- $1.13
- Avg volume (3M)
- —
- Shares outstanding
- 42.95M
- Employees
- 296
- Next earnings
- —
About Pulmonx Corporation
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
- ISIN
- US7458481014
- Founded
- 1995
- Listed since
- Oct 1, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Health Care Equipment & Supplies companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Abbott LaboratoriesNYSE: ABT | $200.95B | $116.13 | -0.46% |
| Intuitive Surgical, Inc.NasdaqGS: ISRG | $131.36B | $371.84 | -0.46% |
| Stryker CorporationNYSE: SYK | $126.81B | $330.59 | +0.85% |
| Medtronic plcNYSE: MDT | $116.66B | $91.14 | -1.89% |
| EssilorLuxottica Société anonymeENXTPA: EL | $85.36B | €160.35 | +0.75% |
| Boston Scientific CorporationNYSE: BSX | $72.26B | $49.86 | +1.73% |
| HOYA CorporationTSE: 7741 | $52.49B | ¥24,995.00 | +0.40% |
| Edwards Lifesciences CorporationNYSE: EW | $52.38B | $90.87 | +0.41% |
Figures last refreshed Aug 18, 2026.